Adarx 制药 ADRX
$13.23 −$0.06 (-0.45%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $13.23 0.00%
开盘$13.73
昨收$13.29
当日区间$12.50 – $13.73
成交量440.0K
市值$1.35B
市盈率（TTM）–
股息率–
股权结构与仓位
谁在持有、谁在做空，以及大资金的流向
机构持股比例51.6%+51.58 个百分点，较上季度
持仓机构数10+10 ，较上季度
内部人近期交易9次买入 / 0次卖出净买入
空头持仓比例1.86% 占流通股回补天数 3.1 · 截至 15 Oct 2026
卖空成交量占比17.1%近5日成交量平均占比
卖空成交量占当日成交量比例
大单净流入，近20个交易日
大单买入减卖出的净额（美元）。该窗口期内：+$614.2K（11个净流入日，9个净流出日）。
按单量净流入，近20个交易日
超大单/大单近似机构级别交易；中单/小单近似散户级别交易。各档买入减卖出净额，按窗口期累计。
已披露的前五大股东合计持有52.0%的流通股。
最大股东
按投资者类型
近期机构持仓变动
| 股东 | 类型 | 期间 | 持股变动 | 新持股比例 |
|---|---|---|---|---|
| OrbiMed Advisors LLC | VC/PE Fund | 2026/Q3 | +24,794,024 | 22.1% |
| Eli Lilly Investment Consulting (Shanghai) Co., Ltd. | VC/PE Fund | 2026/Q3 | +11,858,655 | 10.6% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +1,962,004 | 1.8% |
| Franklin Resources | Mutual Fund | 2026/Q3 | +466,391 | 0.4% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +50,086 | 0.0% |
| Columbia Management Investment Advisers, LLC | Mutual Fund | 2026/Q3 | +8,520 | 0.0% |
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +4,548 | 0.0% |
| Eli Lilly Investment Consulting (Shanghai) Co., Ltd. | VC/PE Fund | 2026/Q3 | +11,858,655 | 10.6% |
| SR One Capital Management, LP | VC/PE Fund | 2026/Q3 | +9,936,661 | 8.9% |
| Li Zhen | Individual/Insider | 2026/Q3 | +5,861,199 | 5.2% |
| Zhen Li | Individual/Insider | 2026/Q3 | +5,861,199 | 5.2% |
| Bcls Fund III Investments, Lp | Private Company | 2026/Q3 | +5,128,970 | 4.6% |
| TCG Crossover Management, LLC | VC/PE Fund | 2026/Q3 | +3,590,279 | 3.2% |
| A. MacLeod | Individual/Insider | 2026/Q3 | +0 | 0.0% |
| Li Zhen | Individual/Insider | 2026/Q3 | +5,861,199 | 5.2% |
按报告期列出的机构买卖动态，变动幅度从大到小排列。
内部人交易
| 日期 | 内部人 | 职位 | 交易类型 | 股数 | 价格 | 交易后持股 |
|---|---|---|---|---|---|---|
| 27 Sep 2026 | OrbiMed Advisors LLC | Private Acquisition | +950,000 | $17.00 | 24,205,789 | |
| 27 Sep 2026 | OrbiMed Advisors LLC | Derivative Exercise and Retained | +23,255,789 | – | 24,205,789 | |
| 27 Sep 2026 | Eli Lilly Investment Consulting (Shanghai) Co., Ltd. | Derivative Exercise and Retained | +11,858,655 | – | 11,858,655 | |
| 27 Sep 2026 | SR One Capital Management, LP | Private Acquisition | +1,600,000 | $17.00 | 9,936,661 | |
| 27 Sep 2026 | SR One Capital Management, LP | Derivative Exercise and Retained | +8,336,661 | – | 9,936,661 | |
| 23 Sep 2026 | Mary Tagliaferri | Independent Director | Initial Statement of Beneficial | +0 | – | 357,056 |
| 23 Sep 2026 | Ying Huang | Independent Director | Initial Statement of Beneficial | +0 | – | 267,792 |
| 23 Sep 2026 | Li Zhen | Chief Executive Officer | Other Derivative Acquisition | +1,024,152 | $17.00 | 1,024,152 |
| 23 Sep 2026 | Li Zhen | Chief Executive Officer | Initial Statement of Beneficial | +0 | – | 5,960,786 |
| 23 Sep 2026 | Robert Ackles | Chief Human Resources Officer | Other Derivative Acquisition | +85,346 | $17.00 | 85,346 |
| 23 Sep 2026 | Robert Ackles | Chief Human Resources Officer | Initial Statement of Beneficial | +0 | – | 335,633 |
| 23 Sep 2026 | A. MacLeod | Chief Scientific Officer | Other Derivative Acquisition | +170,692 | $17.00 | 170,692 |
| 23 Sep 2026 | A. MacLeod | Chief Scientific Officer | Initial Statement of Beneficial | +0 | – | 667,023 |
| 23 Sep 2026 | Ryan Fisk | CFO & Chief Business Officer | Other Derivative Acquisition | +170,692 | $17.00 | 170,692 |
| 23 Sep 2026 | Ryan Fisk | CFO & Chief Business Officer | Initial Statement of Beneficial | +0 | – | 865,864 |
| 23 Sep 2026 | Rui Zhu | Chief Technology Officer | Other Derivative Acquisition | +512,076 | $17.00 | 512,076 |
| 23 Sep 2026 | Rui Zhu | Chief Technology Officer | Initial Statement of Beneficial | +0 | – | 1,277,859 |
数据来自Form 4/Form 144申报文件。负数为减持（出售、赠予或代扣税款股份），正数为增持。
空头持仓（按报告期）
| 报告日期 | 空头股数 | 占流通股比例 | 回补天数 |
|---|---|---|---|
| 15 Oct 2026 | 1,903,521 | 1.9% | 3.1 |
| 30 Sep 2026 | 1,163,375 | 1.1% | 1.7 |
暂无评论——快来第一个聊聊 ADRX。
登录后参与讨论。